Hostname: page-component-7c8c6479df-xxrs7 Total loading time: 0 Render date: 2024-03-18T13:49:35.994Z Has data issue: false hasContentIssue false

Secondary measles vaccine failures identified by measurement of IgG avidity: high occurrence among teenagers vaccinated at a young age

Published online by Cambridge University Press:  01 April 2000

M. PAUNIO
Affiliation:
Department of Public Health, University of Helsinki, Finland
K. HEDMAN
Affiliation:
Department of Virology, University of Helsinki, Finland
I. DAVIDKIN
Affiliation:
Department of Infectious Disease Epidemiology, National Public Health Institute of Finland, Helsinki, Finland
M. VALLE
Affiliation:
Department of Infectious Disease Epidemiology, National Public Health Institute of Finland, Helsinki, Finland
O. P. HEINONEN
Affiliation:
Department of Public Health, University of Helsinki, Finland
P. LEINIKKI
Affiliation:
Department of Infectious Disease Epidemiology, National Public Health Institute of Finland, Helsinki, Finland
A. SALMI
Affiliation:
Department of Virology, University of Turku, Finland
H. PELTOLA
Affiliation:
Hospital for Children and Adolescents, Helsinki University Central Hospital, Helsinki, Finland
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Failure to seroconvert (primary vaccine failure) is believed to be the principal reason (approx. > 95%) why some vaccinees remain susceptible to measles and is often attributed to the persistence of maternal antibodies in children vaccinated at a young age. Avidity testing is able to separate primary from secondary vaccine failures (waning and/or incomplete immunity), but has not been utilized in measles epidemiology. Low-avidity (LA) and high-avidity (HA) virus-specific IgG antibodies indicate primary and secondary failure, respectively. Measles vaccine failures (n = 142; mean age 10·1 years, range 2–22 years) from an outbreak in 1988–9 in Finland were tested for measles–virus IgG avidity using a protein denaturating EIA. Severity of measles was recorded in 89 failures and 169 non-vaccinees (mean age 16·2 years, range 2–22 years). The patients with HA antibodies (n = 28) tended to have clinically mild measles and rapid IgG response. Among failures vaccinated at < 12, 12–15 and > 15 months of age with single doses of Schwarz-strain vaccine in the 1970s, 50 (95% CI 1–99), 36 (CI 16–56) and 25% (CI 8–42) had HA antibodies, respectively. When a single measles, mumps and rubella (MMR) vaccine had been given after 1982 at 15 months of age, only 7% (CI 0–14) showed HA antibodies. Omitting re-vaccinees and those vaccinated at < 15 months, Schwarz-strain recipients had 3·6 (CI 1·1–11·5) higher occurrence of HA responses compared to MMR recipients. Apart from one municipality, where even re-vaccinees had high risk of primary infection, 89% (CI 69 to ∼ 100) of the infected re-vaccinees had an HA response. Secondary measles-vaccine failures are more common than was more previously thought, particularly among individuals vaccinated in early life, long ago, and among re-vaccinees. Waning immunity – even among individuals vaccinated after 15 months of age, without the boosting effect of natural infections should be considered a relevant possibility in future planning of vaccination against measles.

Type
Research Article
Copyright
© 2000 Cambridge University Press